Globe News Wire
02 Mar 2026, 14:47 UTC · 28w ago
Verdict
Headline takes no side. We score ADMA −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Ultragenyx disclosed that its ORBIT and COSMIC Phase 3 programs for setrusumab failed to meet their primary endpoints.
So whatFailure of Phase 3 trials for a core drug candidate is a major fundamental blow to a biopharmaceutical company's pipeline and valuation.
More negative than 99% of claims this week
Ultragenyx shares lost more than 42% of their value in a single trading day following the trial result disclosure.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 93% of claims this week
A class action lawsuit has been filed against Ultragenyx alleging the company misrepresented the efficacy results of the setrusumab trials.
More negative than 74% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is the subject of a class action lawsuit announced by Berger Montague.
More negative than 96% of ticker scores this week
The company is the subject of a class action lawsuit announced by Berger Montague.
More negative than 96% of ticker scores this week
The company is facing a class action lawsuit following a 42% share price drop after failing to meet primary endpoints in Phase 3 clinical trials.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2d ago
−41.5%
Price agrees with the score
$9.11 vs $15.57 close before publication (Feb 27) · not market-adjusted
ADMA chart →
